aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Auron Therapeutics, founded with the mission to revolutionize cancer treatment, focuses on transforming malignant cells into normal functioning cells rather than traditional cell-killing methods. The company offers next-generation targeted cancer therapies aimed at solid tumors and hematological malignancies. Utilizing a proprietary database of single-cell genomic data and an AI-powered computational platform, Auron Therapeutics identifies and targets dysregulated cell states to develop innovative cancer treatments.
Notable affiliated individuals and investors include leading experts in oncology and biotechnology, though specific names are not provided. Key achievements include the development of a comprehensive atlas to map cancer cell states, which has significantly advanced their research capabilities. Auron Therapeutics' impact lies in its potential to shift the paradigm of cancer treatment, offering hope for more effective and less harmful therapeutic options.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Cancer Therapies
Technology
AI, Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Auron Therapeutics founded?
Auron Therapeutics was founded in 2018.
Where is Auron Therapeutics’s headquarters located?
Auron Therapeutics’s headquarters is located in Wellesley, MA, US.
When was Auron Therapeutics’s last funding round?
Auron Therapeutics’s most recent funding round was for $48M (USD) in July 2022.
How many employees does Auron Therapeutics have?
Auron Therapeutics has 28 employees as of Feb 5, 2024.
How much has Auron Therapeutics raised to-date?
As of July 05, 2023, Auron Therapeutics has raised a total of $61.4M (USD) since Jul 20, 2022.
Add Comparison
Total Raised to Date
$61.4M
USD
Last Update Jul 20, 2022
Last Deal Details
$48M
USD
Jul 20, 2022
Series A
Total Employees Over Time
28
As of Feb 2024
Auron Therapeutics Address
7 Norwich Road
Wellesley,
Massachusetts
02481
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts